Valuations For Purchase Accounting / US GAAP / IFRS
Sorbus Advisors LLC offers unparalleled experience in the valuation of intangible assets to satisfy the most demanding financial reporting, tax planning, and dispute resolution needs. ASC 805 IFRS 3, fair value.
Purchase Price Allocation (ASC 805) Benchmarking Study IT 2019
Since 2015, Sorbus Advisors LLC has been publishing its annual purchase accounting benchmarking report. This featured study covers 134 transactions in the Information Technology industry. It provides a quick visual reference for the values and useful lives of intangible assets and goodwill as recognized in purchase accounting. Enjoy the publication and feel free to contact us directly with any questions.
Purchase Price Allocation Benchmarking Study | IT 2018
We are pleased to present the results of our purchase price allocations benchmarking study for Information Technology acquisitions completed in 2017. While no two acquisitions are the same, common themes in the valuation of intangibles and goodwill can be found along industry lines. Information Technology companies commonly rely on such identifiable intangible assets as developed technology, in-process research and development, customer relationships, and trade names. However, even within IT, companies pursue wildly different and unique business models. Our analysis aims to identify patterns within narrowly defined industry segments.
Low 409A – More Than Meets The Eye
Early stage start-ups often hope to grant stock options at the lowest possible price. The motivations are clear especially when an optionee plans to exercise immediately upon the grant. Other situations are not always so clear-cut. We discuss several ways of how lowball valuations can backfire.
2015 Goodwill / Intangibles Benchmarking BioPharmaceuticals
We studied purchase price allocations in BioPharmaceutical industry titled “Valuation of Goodwill and Intangibles in 2015 BioPharmaceutical Transactions.” The study focused on recognition, valuation, and determination of useful lives of pertinent intangible assets, contingent considerations and goodwill.
ASC 820 Portfolio Valuation Webinar
The following discussion is provided from a valuation specialist perspective. The information contained in this presentation is not meant to be investment, tax or financial reporting advice. Please consult with a qualified professional for further information on your specific situation.
Updated Common Stock Valuation Guidance
Valuation of privately issued securities is a major concern among founders, employees, regulatory agencies and investors. Meaningful value conclusions help measure performance, assess strategic alternatives, and facilitate dialog among various stakeholders.
ASC 805 6 Key Considerations
For most companies, Financial Accounting Standards Board Accounting Standards Codification Topic 805 (ASC 805) has been in effect since 2009. While the recent wave of acquisition activity provided lessons in implementing the new standards, more transaction experience is needed to understand the full impact of ASC 805.
Social Gaming Purchase Accounting Benchmarking
The Social Gaming has been one of the most active sectors for M&A transactions in the global technology industry. With the promise of significant growth and almost immediate profitability, social game developers provide for attractive acquisition targets in buy vs. build strategy.
BioPharmaceutical Valuations in Purchase Accounting
Accounting Standard Codification Topic 805 (“ASC 805”), Business Combinations, was designed to provide additional transparency in purchase accounting. The biopharmaceutical industry is a clear beneficiary.
LendingClub 3Q 2011 Vintage Update
LendingClub has issued over $7 billion of notes, funded by retail and institutional investors, through its state-of-the-art lending platform. The notes are straightforward fixed rate loans that retail borrowers (and now businesses) pay off in three or five years. While the payment plan is simple, there is nothing trivial about calculating true investment performance.
Biotech Stock Trading Patterns and Volatility
Biotechnology companies, especially those that concentrate on developing therapeutic candidates, tend to experience large ups and downs associated with the progress of their clinical programs. An individual therapeutic candidate can promise billions in potential sales, while the likelihood of making it from pre‐clinical stages to full marketing approval by the FDA can be de minimis. Every success or failure on this path can lead to significant changes in value.
2014 Goodwill / Intangible Benchmarking Software & Services
The Financial Accounting Standards Board (FASB) and the Securities and Exchange Commission (SEC) have consistently emphasized the importance of accurate business combination accounting. We studied the accounting purchase price allocation results with the focus on goodwill and identifiable intangible assets for Software and Services companies.